1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703) 308-1152.

Slides:



Advertisements
Similar presentations
Slides to Accompany Artful Prior Art. Derwent GENESEQ Database Collection of patented DNA sequences –10 or more base pairs Coverage from 1981 Feb. 2001:
Advertisements

Unity of Invention Biotechnology Practice Julie Burke USPTO TC1600 Special Program Examiner.
SNP Applications statwww.epfl.ch/davison/teaching/Microarrays/snp.ppt.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
1 Types of Vaccines and Patentability Considerations Christina Chan Supervisory Primary Examiner Art Unit 1644 Phone:
Utility and Written Description Steve Kunin Deputy Commissioner for Patent Examination Policy Esther Kepplinger Deputy Commissioner for Patent Operations.
Benefit to Society Good Science. Human genes claimed in granted U.S. patents Jensen and Murray, Science 310: (14 Oct. 2005) “Specifically, this.
More on Restriction Practice Jim Housel SPE, Art Unit 1648 (703)
1 Homology Language Brian R. Stanton Quality Assurance Specialist Technology Center 1600 U.S. Patent and Trademark Office (703)
Diagnostics: Patent Eligibility and the Industry Perspective
1. 2 Biotechnology Inventions: Genes & Life Forms and the Impact of Patenting on Upstream Science Nancy J. Linck, Ph.D., J.D. Deputy General Counsel Intellectual.
Gene Therapy: Overcoming Enablement Rejections Karen M. Hauda Supervisory Patent Examiner Art Unit 1632 (703)
Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Animals and Transgenesis Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Transgenic Animals — How they are made Examination of Transgenic.
CS177 Lecture 9 SNPs and Human Genetic Variation Tom Madej
Dr. Almut Nebel Dept. of Human Genetics University of the Witwatersrand Johannesburg South Africa Significance of SNPs for human disease.
Assessing Compliance with the Utility Requirement of 35 U.S.C. § 101 based on the Sequence Homology Dave Nguyen, tQAS TC
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Examining Issues When.
Genome Browsers Ensembl (EBI, UK) and UCSC (Santa Cruz, California)
A Look at Personalized Medicine Quality Assurance Specialist
Human Genetics Overview.
Issues in Patenting Proteins Jon P Weber, SPE 1657.
Office hours Wednesday 3-4pm 304A Stanley Hall Review session 5pm Thursday, Dec. 11 GPB100.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
DbSNP: the NCBI database of genetic variation S. T. Sherry, M.H. Ward, M. Kholodov, J. Baker, L. Phan, E. M. Smigielski and K. Sirotkin, Nucleic Acids.
Georgia Wiesner, MD CREC June 20, GATACAATGCATCATATG TATCAGATGCAATATATC ATTGTATCATGTATCATG TATCATGTATCATGTATC ATGTATCATGTCTCCAGA TGCTATGGATCTTATGTA.
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Analyzing DNA Differences PHAR 308 March 2009 Dr. Tim Bloom.
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
© 2011 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is the property of Barnes & Thornburg LLP which may not be reproduced,
Patenting Interfering RNA
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
SNPs Daniel Fernandez Alejandro Quiroz Zárate. A SNP is defined as a single base change in a DNA sequence that occurs in a significant proportion (more.
Manipulation of DNA. Restriction enzymes are used to cut DNA into smaller fragments. Different restriction enzymes recognize and cut different DNA sequences.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
CS177 Lecture 10 SNPs and Human Genetic Variation
SNP Haplotypes as Diagnostic Markers Shrish Tiwari CCMB, Hyderabad.
DNA TECHNOLOGY AND BIOTECHNOLOGY PAGES Chapter 10.
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
[ w w w. d u a n e m o r r i s. c o m ] ● ©2008 Duane Morris LLP. All Rights Reserved. Duane Morris is a registered service mark of Duane Morris LLP. ●
Julia N. Chapman, Alia Kamal, Archith Ramkumar, Owen L. Astrachan Duke University, Genome Revolution Focus, Department of Computer Science Sources
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Patent Protection of Biotechnological Inventions in China Gesheng Huang Partner Zhongzi Law Office AIPLA Spring Meeting, May 12-14, 2011, San Francisco,
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
Lecture 6. Functional Genomics: DNA microarrays and re-sequencing individual genomes by hybridization.
“The Squeeze” Art and Enablement Together Yvonne L. Eyler, SPE AU 1646.
Bioinformatics and Computational Biology
Patenting Interfering RNA John LeGuyader – SPE Art Unit 1635 (571)
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
The International Consortium. The International HapMap Project.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Myriad The Future of DNA Claims Mercedes Meyer, Ph.D., JD AIPLA 1.
Genomics Chapter 18.
Notes: Human Genome (Right side page)
1 Utility Guidelines, Homology Claims and Anti-Sense Molecule Claims Drew Hissong, Ph.D. dhissong*sughrue.com Sughrue Mion, PLLC
Single Nucleotide Polymorphisms (SNPs
X Chromosome Inactivation
Introduction to bioinformatics lecture 11 SNP by Ms.Shumaila Azam
In these studies, expression levels are viewed as quantitative traits, and gene expression phenotypes are mapped to particular genomic loci by combining.
SNPs and CNPs By: David Wendel.
Examination Practice in Applications Presenting “Reach-Through Claims”
Examination Issues: Immunology
Presentation transcript:

1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)

2 Communication and Cooperation ä Issues in Biotechnology are complex ä Communication ä Interviews ä Focus on Invention ä Cooperation ä Open, frank discussions ä Practice Specialists ä Prosecution ä Agree on the invention ä Work out the claims ä Identify the issues

3 A Gene by Another Name???? Single Nucleotide Polymorphism - A single base difference in a DNA sequence among individuals.

4 SNPs ä Association of sequence variations with heritable phenotypes ä Used in genotyping, ä Genomic and drug research ä Clinical diagnostics ä Markers in identifying genes and genetic differences that may determine the response of a given patient to disease and disease treatment.

5 Interesting Fact SNPs are predicted to occur once every bases at the gene level.

6 Private and Public Sector Efforts ä 2,841,419 SNPs currently (as of 3/22/01) in public database ä SNP Consortium ä Objective: To identify 300,000 SNPs and map 150,000 SNPs evenly distributed throughout the human genome at a 95 percent confidence level.

7 Magnitude 15-20% of patent applications in Art Unit 1655, or about applications per year and climbing.

8 Patentability Issues ä Novelty ä Obviousness ä Utility ä Written Description

9 Novelty ä Claim: ä An isolated and purified nucleic acid comprising SEQ ID NO: 1. ä Fact: SEQ ID NO: 1 differs from the prior art sequence by one nucleotide. ä The prior art sequence is a breast cancer related DNA.

10 Novelty ä If the prior art does not teach the specific polymorphism, a claim to an isolated nucleic acid with the polymorphism is usually found to be allowable over the prior art.

11 Obviousness ä Claim: ä An isolated and purified DNA comprising SEQ ID NO: 1. ä The prior art teaches the source of DNA (e.g. a specific patient’s sample) ä The specification teaches that the SNP containing DNA was isolated from this same source. ä The prior art might provide the motivation to go to this particular source of DNA to isolate additional variants of the gene.

12 Novelty ä Claim: ä An isolated nucleic acid encoding SEQ ID NO: 2. ä Fact: SEQ ID NO: 2 is a known, well characterized protein. ä The prior art teaches SEQ ID NO: 2 and also teaches a DNA that encodes SEQ ID NO: 2, however the DNA encoding SEQ ID NO: 2 in the prior art is not the same as that which applicant has disclosed.

13 Novelty ä If the nucleotide change does not result in an amino acid change, the prior art reference is anticipatory.

14 Utility Considerations for Single Nucleotide Polymorphisms (SNPs)

15 Scenarios ä A disclosure details single nucleotide polymorphisms present relative to a reference nucleic acid molecule. The reference nucleic acid: ä 1.Encodes a protein with a well-established utility or which is supported in the specification by a specific, substantial, and credible utility. ä A.The polymorphism does not affect the encoded protein. ä B.The polymorphism alters the nature of the encoded protein in an undisclosed manner. ä 2.Does not encode a protein with a specific, substantial, and credible utility or a well-established utility, but the disclosed polymorphism is disclosed as correlative to some disease or condition. ä 3.Does not encode a protein with a specific, substantial, and credible utility or a well-established utility, and the disclosed polymorphism is not disclosed as correlative to some disease or condition.

16 Scenario 1A ä The reference nucleic acid (SEQ ID NO: 1) encodes a protein (SEQ ID NO: 2) with a well-established utility or which is supported in the specification by a specific, substantial, and credible utility. The polymorphism does not affect the encoded protein. ä Claim: A nucleic acid comprising SEQ ID NO: 1, wherein the nucleotide at position 128 is replaced with a G.

17 Scenario 1A ä Based upon the fact pattern, the claimed nucleic acid will still encode a protein that has a specific, substantial, and credible utility or a well- established utility. ä Therefore, there is no utility (or enablement or written description) issue.

18 Scenario 1B ä The reference nucleic acid (SEQ ID NO: 1) encodes a protein (SEQ ID NO: 2) with a well-established utility or which is supported in the specification by a specific, substantial, and credible utility. The polymorphism alters the nature of the encoded protein in an undisclosed manner. ä Claim: A nucleic acid comprising SEQ ID NO: 1, wherein the nucleotide at position 128 is replaced with a G.

19 Scenario 1B ä Based upon the fact pattern, the claimed nucleic acid will not encode a protein that would support a specific, substantial, and credible utility or well- established utility for the claimed polymorphic molecule. ä Therefore, there is a utility question that is addressed in Scenario 2 or 3.

20 Scenario 2 ä A disclosure details single nucleotide polymorphisms present relative to a reference nucleic acid molecule. The reference nucleic acid does not encode a protein with a specific, substantial, and credible utility or a well- established utility, but the disclosed polymorphism is disclosed as correlative to some disease or condition. ä Claim: A nucleic acid comprising SEQ ID NO: 1, wherein the nucleotide at position 128 is replaced with a G.

21 Scenario 2 ä Based upon the fact pattern, the claimed nucleic acid will not encode a protein that would support a specific, substantial, and credible utility or well- established utility for the claimed polymorphic molecule. ä However, the nucleic acid consisting of SEQ ID NO: 1, wherein the nucleotide at position 128 is replaced with a G, does have a specific, substantial, and credible utility.

22 Scenario 2 ä Note that the appropriate scope of the claim will be determined by consideration of: ä 35 U.S.C. §112, first paragraph, adequate written description ä 35 U.S.C. §112, first paragraph, enablement ä 35 U.S.C. §102/103 - nature of prior art

23 Scenario 3 ä A disclosure details single nucleotide polymorphisms present relative to a reference nucleic acid molecule. The reference nucleic acid does not encode a protein with a specific, substantial, and credible utility or a well- established utility, and the disclosed polymorphism is not disclosed as correlative to some disease or condition or other patentable utility. ä Claim: A nucleic acid comprising SEQ ID NO: 1, wherein a G is present at position 128.

24 Scenario 3 ä Based upon the fact pattern, the claimed nucleic acid will not encode a protein that would support a specific, substantial, and credible utility or well- established utility for the claimed polymorphic molecule. ä In addition, there is no disclosed specific, substantial, and credible or well-established utility for the nucleic acid of SEQ ID NO: 1, wherein the nucleotide at position 128 is replaced with a G.

25 Scenario 3 ä Therefore, the claim will be rejected under 35 U.S.C. §101 as failing to be supported by a specific, substantial, and credible utility or a well- established utility.

26 Scenario 3: What can you do? ä Provide evidence that the claimed nucleic acid would have a use that is supported by the as-filed specification, e.g. ä A particular useful population marker ä A particular disease marker ä Be careful that your use is supported by the specification or submit evidence that the use would have been “well-established”.

27 Written Description and SNPs Scenario 1 An isolated polynucleotide comprising SEQ ID NO: 1. SEQ ID NO: 1 is a 100mer obtained from a human glioblastoma cDNA library. SEQ ID NO: 1 is homologous to a known DNA molecule that encodes a useful protein.

28 Claim Scope ä Claim reads on any nucleic acid comprising SEQ ID NO: 1 ä Gene ä Full ORF ä Fusion constructs, etc. ä cDNAs

29 Single Species Actual reduction to practice of a single species. ä SEQ ID NO: 1.

30 Scenario 2 ä An isolated polynucleotide comprising SEQ ID NO: 1. ä SEQ ID NO: 1 is a Full length Open Reading Frame (ORF) cDNA sequence that is shown in the specification to encode SEQ ID NO: 2 (a member of a well known family of proteins).

31 Written Description ä Claim: An isolated polynucleotide comprising SEQ ID NO: 1. ä SEQ ID NO: 1 is a full length ORF that encodes SEQ ID NO: 2 ä Claim reads on the ORF with any additional elements ä The disclosed invention is based upon the ORF; any additional elements would have been considered conventional and well known in the art ä Adequate Written Description

32